Aging
Navigate
Submit an Article
Research Paper|Volume 14, Issue 24|pp 10093—10106

Development of a 7-miRNA prognostic signature for patients with bladder cancer

Yingjie Xv1, Ming Qiu2, Zhaojun Liu3, Mingzhao Xiao1, Fen Wang4
  • 1Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, Yuzhong 400016, China
  • 2Department of Urology, The People’s Hospital of Dazu, Chongqing, Dazu 402360, China
  • 3Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, Yuzhong 400016, China
  • 4Department of Pathology, The People’s Hospital of Dazu, Chongqing, Dazu 402360, China
* Equal contribution
# Co-first authors
Received: August 20, 2021Accepted: February 12, 2022Published: December 21, 2022
https://doi.org/10.18632/aging.204447

Copyright: © 2022 Xv et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Background: Bladder carcinoma (BC) represents one of the most prevalent malignant cancers, while predicting its clinical outcomes using traditional indicators is difficult. This study aimed to develop a miRNA signature for the prognostic prediction of patients with BC.

Materials and Methods: MiRNAs that expressed differentially were identified between 413 BC and 19 non-tumor patients, whose prognostic values were evaluated using univariate and multivariate Cox regression analyses. The independent prognostic factors were screened out and were used to establish a signature. The risk score of the signature was calculated. Receiver operating characteristic (ROC) curves and Kaplan-Meier curves were used to verify the predictive performance of the miRNA signature and the risk score. A nomogram was constructed which integrated with the miRNA signature and clinical parameters. Experiments were performed.

Results: 7 prognosis related miRNAs were selected as independent risk factors, and a 7-miRNA signature was constructed, with an area under ROC (AUC) of 0.721. The 7-miRNA-signature based risk score acts as an independent prognostic factor, with satisfactory predictive performance (AUC = 0.744). Increased miR-337-3p expressions were detected in tumor samples and BC cell lines than in non-tumorigenic tissues and cell lines. Experiments suggested that miR-337-3p induces the proliferation, migration, and invasion of BC cells.

Conclusion: The constructed 7-miRNA signature is a promising biomarker for predicting the prognosis of patients with BC, and miR-337-3p may act as a candidate therapeutic target in BC treatments.